Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights.
Asumi IesatoStephanie LiGiovanni RotiMichele R HackerAndrew H FischerCarmelo NuceraPublished in: The Journal of clinical endocrinology and metabolism (2021)
This is the first thyroid-specific model of lenvatinib therapeutic efficacy against pericyte viability, which disadvantages BRAFWT/V600E-PTC growth. Assessing pericyte abundance in patients with PTC could be essential to selection rationales for appropriate targeted therapy with lenvatinib.